552 related articles for article (PubMed ID: 24145221)
1. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study.
Muscatello MR; Pandolfo G; Micò U; Lamberti Castronuovo E; Abenavoli E; Scimeca G; Spina E; Zoccali R; Bruno A
J Clin Psychopharmacol; 2014 Feb; 34(1):129-33. PubMed ID: 24145221
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
3. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
[TBL] [Abstract][Full Text] [Related]
4. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
5. A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment.
Harvey PD; Sacchetti E; Galluzzo A; Romeo F; Gorini B; Bilder RM; Loebel AD
Schizophr Res; 2008 Oct; 105(1-3):138-43. PubMed ID: 18077136
[TBL] [Abstract][Full Text] [Related]
6. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study.
Nielsen J; Emborg C; Gydesen S; Dybbro J; Aagaard J; Haderup K; Glyngdal P; Fabricius S; Thode D; Lublin H; Andersen T; Damkier P; Taylor D
J Clin Psychopharmacol; 2012 Apr; 32(2):173-8. PubMed ID: 22367659
[TBL] [Abstract][Full Text] [Related]
7. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
[TBL] [Abstract][Full Text] [Related]
8. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
9. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
10. A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
Li CH; Shi L; Zhan GL; Rao SZ; Zhang H
Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2136-40. PubMed ID: 23893178
[TBL] [Abstract][Full Text] [Related]
11. Clozapine alone versus clozapine and risperidone with refractory schizophrenia.
Honer WG; Thornton AE; Chen EY; Chan RC; Wong JO; Bergmann A; Falkai P; Pomarol-Clotet E; McKenna PJ; Stip E; Williams R; MacEwan GW; Wasan K; Procyshyn R;
N Engl J Med; 2006 Feb; 354(5):472-82. PubMed ID: 16452559
[TBL] [Abstract][Full Text] [Related]
12. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
13. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
Schizophr Res; 2009 Aug; 113(1):112-21. PubMed ID: 19606529
[TBL] [Abstract][Full Text] [Related]
14. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
Potkin SG; Weiden PJ; Loebel AD; Warrington LE; Watsky EJ; Siu CO
Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone.
Kuwilsky A; Krumm B; Englisch S; Dressing H; Zink M
Pharmacopsychiatry; 2010 Aug; 43(6):216-20. PubMed ID: 20589598
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
Mencacci C;
Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
[TBL] [Abstract][Full Text] [Related]
17. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
[TBL] [Abstract][Full Text] [Related]
18. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
19. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study.
Ziegenbein M; Kropp S; Kuenzel HE
Clin Neuropharmacol; 2005; 28(5):220-4. PubMed ID: 16239761
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial.
Cipriani A; Accordini S; Nosè M; Purgato M; Girlanda F; Tansella M; Barbui C
J Clin Psychopharmacol; 2013 Aug; 33(4):533-7. PubMed ID: 23775051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
